Subtype
Digestive System Carcinoma
CI-CAN-00000812Explore in graph →
- NCIt
- C96963
Loading cancer entity…
Subtype
CI-CAN-00000812Explore in graph →
Variants & evidence
282 evidence items mapped to this entity or its descendants, grouped by molecular profile, then therapy. 50 items per page.
| Therapy | Cancer | Type | Level | Direction · significance | Rating (1–5) | Status | Evidence | Source |
|---|---|---|---|---|---|---|---|---|
| EGFR L747_P753delinsS1 | ||||||||
| Erlotinib | Pancreatic Adenocarcinoma | Predictive | C | Supports Sensitivity Response | 3 | accepted | EID6005Patients with recurrent pancreatic adenocarcinoma was treated with gemcitabine + nab-paclitaxel, FOLFIRINOX and docetaxel + irinotecan. After failure of these treatment, a tumor specimen from the panc… (full text at CIViC) PMID 28874593 · Cecchini et al., 2017 · Open in CIViC | civic |
| EGFR L861Q1 | ||||||||
| Afatinib | Esophageal Squamous Cell CarcinomaALIAS | Predictive | D | Supports Sensitivity Response | 4 | submitted | EID9679This retrospective preclinical study assessed the efficacy of afatinib towards esophageal squamous cell carcinoma (ESCC) cell lines expressing EGFR L861Q mutation. In one experiment, a ESCC KYSE270 EG… (full text at CIViC) PMID 27207775 · Nakamura et al., 2016 · Open in CIViC | civic |
| EGFR Mutation1 | ||||||||
| (prognostic) | Cholangiocarcinoma | Prognostic | B | Supports Poor Outcome | 2 | submitted | EID10359In a study of 137 biliary tract carcinomas, 13 patients were identified to have EGFR variants in exons 18-21 (no other exons were evaluated). EGFR variants were associated with worse survival in univa… (full text at CIViC) PMID 24372748 · Chang et al., 2014 · Open in CIViC | civic |
| EGFR Overexpression4 | ||||||||
| (prognostic) | Esophageal Squamous Cell CarcinomaALIAS | Prognostic | B | Supports Poor Outcome | 3 | accepted | EID78455 tumor samples were analyzed for EGFR expression using IHC. PFS and OS was shorter for the EGFR high expressing group (18 pts) than for the low to moderate expression group (37 pts). PFS: 5.8 ± 0.5 … (full text at CIViC) PMID 26459251 · Jia et al., 2016 · Open in CIViC | civic |
| Unspecified therapy | Esophageal Squamous Cell CarcinomaALIAS | Predictive | B | Does Not Support Sensitivity Response | 3 | rejected | EID833Expression of EGFR in 55 samples of esophageal squamous cell carcinoma with IHC was not predictive of response to EGFR inhibitor nimotuzumab. EGFR overexpression was related to poor OS and PFS. PMID 26459251 · Jia et al., 2016 · Open in CIViC | civic |
| (prognostic) | Esophageal Squamous Cell CarcinomaALIAS | |||||||
| EGFR Overexpression + KRAS MutationEGFRKRAS3 | ||||||||
| Cetuximab | Colorectal Adenocarcinoma | Predictive | B | Supports Adverse Response | 3 | submitted | EID11059The Medical Research Council (MRC) COIN trial consisted of patients with histologically confirmed adenocarcinoma of the colon or rectum, inoperable metastatic or locoregional measurable disease, and w… (full text at CIViC) PMID 21641636 · Maughan et al., 2011 · Open in CIViC | civic |
| (prognostic) | Colorectal Adenocarcinoma | Prognostic | B | Supports Poor Outcome | 3 | submitted | EID11058The Medical Research Council (MRC) COIN trial consisted of patients with histologically confirmed adenocarcinoma of the colon or rectum, inoperable metastatic or locoregional measurable disease, and w… (full text at CIViC) PMID 21641636 · Maughan et al., 2011 · Open in CIViC | civic |
| Cetuximab + ChemotherapyCombination | Colorectal Adenocarcinoma | |||||||
| EGFR T790M2 | ||||||||
| (prognostic) | Cholangiocarcinoma | Prognostic | B | Supports Better Outcome | 1 | submitted | EID10358In a Thai cohort of 81 patients with cholangiocarcinoma, 17 patients harbored EGFR variants, 9 of which were T790M. EGFR T790M variants were associated with longer overall survival than patients with … (full text at CIViC) PMID 29066915 · Trachu et al., 2017 · Open in CIViC | civic |
| Osimertinib | Pancreatic Adenocarcinoma | Predictive | C | Does Not Support Sensitivity Response | 2 | accepted | EID6006Patients with recurrent pancreatic adenocarcinoma was treated with gemcitabine + nab-paclitaxel, FOLFIRINOX and docetaxel + irinotecan. After failure of these treatment, a tumor specimen from the panc… (full text at CIViC) PMID 28874593 · Cecchini et al., 2017 · Open in CIViC | civic |
| EGFR Y69FS*111 | ||||||||
| Erlotinib | Esophageal Squamous Cell CarcinomaALIAS | Predictive | D | Supports Resistance | — | submitted | EID4808In an in vitro study, an esophageal squamous cell carcinoma cell line KYSE70 expressing EGFR Y69fs*11 mutation was associated with insensitivity to erlotinib treatment (IC50=4.31uM). Resistance was de… (full text at CIViC) PMID 27207775 · Nakamura et al., 2016 · Open in CIViC | civic |
| EIF4EBP1 PHOSPHORYLATION1 | ||||||||
| Everolimus | Gastric Adenocarcinoma | Predictive | D | Supports Sensitivity Response | 2 | accepted | EID9188 gastric cancer cell lines were treated with the MTOR inhibitor everolimus. Cell proliferation was effectively inhibited in 3 cell lines by everolimus. Phosphorylated EIF4EBP1 (T37/46, T70) levels we… (full text at CIViC) PMID 23340172 · Nishi et al., 2013 · Open in CIViC | civic |
| NTRK3 Fusion2 | ||||||||
| (oncogenic) | Pancreatic Ductal Adenocarcinoma | Oncogenic | C | Supports Oncogenicity | 1 | accepted | EID10484Whole genome sequencing and RNAseq were performed on 400 patients with resected or locally advanced/metastatic Pancreatic Ductal Adenocarcinoma (PDAC). Immunohistochemistry (IHC) analysis was performe… (full text at CIViC) PMID 34583947 · Allen et al., 2023 · Open in CIViC | civic |
| 〃 | Colon Adenocarcinoma | Oncogenic | C | Supports Oncogenicity | 1 | accepted | EID10506From a retrospective review of 38,095 tumor samples from 33,997 patients using DNA sequencing (MSK-IMPACT) and RNA sequencing (MSK-Fusion panel) identified 87 tumors with NTRK1-3 fusions. Two cases of… (full text at CIViC) PMID 31375766 · Solomon et al., 2020 · Open in CIViC | civic |
| EP300 Y1414C1 | ||||||||
| (oncogenic) | Esophageal Squamous Cell CarcinomaALIAS | Oncogenic | D | Supports Oncogenicity | 2 | submitted | EID9573Mutations in histone modifier genes were analyzed in exome sequence data from 113 esophageal squamous cell carcinoma tumors. KYSE-150 and KYSE-450 ESCC cell lines were depleted of EP300 using shRNA, t… (full text at CIViC) PMID 25151357 · Gao et al., 2014 · Open in CIViC | civic |
| ERBB2 Amplification9 | ||||||||
| (oncogenic) | Pancreatic Ductal Adenocarcinoma | Oncogenic | D | Supports Oncogenicity | 3 | submitted | EID11563The ERRB2 amplification effect in PDAC was studied through CAPAN1 cells and ERBB2-KO (knockout) CAPAN1 cells that were KO using CRISPR (Figure 4C, Supp Table 4), with a 90% reduction of ERBB2 compared… (full text at CIViC) PMID 31046123 · Li et al., 2020 · Open in CIViC | civic |
| Afatinib | Pancreatic Adenocarcinoma | Predictive | D | Supports Sensitivity Response | 2 | accepted | EID962Afatinib was growth-inhibitory for three pancreatic cancer cell lines but cytotoxic only toward BxPC3 (KRAS wt) and Capan-2 (KRAS mut) cells, both of which express high levels of EGFR, ERBB2, and ERBB… (full text at CIViC) PMID 26668065 · Huguet et al., 2016 · Open in CIViC | civic |
| Lapatinib | Gastric Adenocarcinoma | Predictive | B | Supports Sensitivity Response | ||||
| ERBB2 E717D1 | ||||||||
| (oncogenic) | Pancreatic Ductal Adenocarcinoma | Oncogenic | D | Supports Oncogenicity | 3 | submitted | EID11555HPNE cells infected with lentiviral vectors containing the variant did show significant phosphorylation of ERBB2 (Supplementary Figure 1) compared to WT (Figure 2A and B). The variant also exhibits an… (full text at CIViC) PMID 31046123 · Li et al., 2020 · Open in CIViC | civic |
| ERBB2 G292R1 | ||||||||
| (oncogenic) | Gallbladder Carcinoma | Oncogenic | D | Supports Oncogenicity | 2 | submitted | EID12117The ERBB2 G292R variant was observed in 1/57 normal/tumor pairs of human gallbladder carcinoma profiled by next-generation sequencing. Human gallbladder cancer cell lines (GBC-SD and NOZ) were transie… (full text at CIViC) PMID 24997986 · Li et al., 2014 · Open in CIViC | civic |
| ERBB2 L755S2 | ||||||||
| (oncogenic) | Pancreatic Ductal Adenocarcinoma | Oncogenic | D | Supports Oncogenicity | 3 | submitted | EID11557HPNE cells infected with lentiviral vectors containing the variant did show significant phosphorylation of ERBB2 (Supplementary Figure 1) compared to WT (Figure 2A and B). The variant also exhibits an… (full text at CIViC) PMID 31046123 · Li et al., 2020 · Open in CIViC | civic |
| Fluorouracil + Leucovorin + TrastuzumabCombination | Colorectal Adenocarcinoma | Predictive | C | Does Not Support Sensitivity Response | 3 | accepted | EID4955Patient was a 35 year old male who was treated with pseudoadjuvant FOLFOX chemotherapy. Patient relapsed and was found to have an ERBB2 L755S kinase domain mutation along with mutations in APC and BRA… (full text at CIViC) PMID 27626067 · Aung et al., 2016 · Open in CIViC | civic |
| ERBB2 L755S + KRAS G12DERBB2KRAS1 | ||||||||
| (oncogenic) | Pancreatic Ductal Adenocarcinoma | Oncogenic | D | Supports Oncogenicity | 3 | submitted | EID11558KRAS G12D-transformed HPNE cells with lentiviral vectors containing the variant significantly increased colony formation in number and size in soft agar compared to infected HPNE cells with the varian… (full text at CIViC) PMID 31046123 · Li et al., 2020 · Open in CIViC | civic |
| ERBB2 Overexpression2 | ||||||||
| Ramucirumab | Gastroesophageal Junction Adenocarcinoma | Predictive | B | Does Not Support Reduced Sensitivity | 2 | submitted | EID7064Given that some results in HER2 gastroesophageal cancer have shown that after first line trastuzumab, second line chemotherapy with trastuzumab (CT) is superior to chemotherapy alone, the authors comp… (full text at CIViC) | civic |
| Trastuzumab | Gastroesophageal Junction Adenocarcinoma | Predictive | B | Supports Sensitivity Response | 3 | submitted | EID7062In a retrospective study of Chinese patients with advanced HER2 positive gastric or gastro-esophageal junction (GEJ) cancer who had progressed on first line trastuzumab, continuation (n = 19) versus … (full text at CIViC) | civic |
| ERBB2 Q679L1 | ||||||||
| (oncogenic) | Pancreatic Ductal Adenocarcinoma | Oncogenic | D | Supports Oncogenicity | 3 | submitted | EID11553HPNE cells infected with lentiviral vectors containing the variant did show significant phosphorylation of ERBB2 (Supplementary Figure 1) compared to WT (Figure 2A and B). The variant also exhibits an… (full text at CIViC) PMID 31046123 · Li et al., 2020 · Open in CIViC | civic |
| ERBB2 R678Q4 | ||||||||
| (oncogenic) | Pancreatic Ductal Adenocarcinoma | Oncogenic | D | Supports Oncogenicity | 3 | submitted | EID11551HPNE cells infected with lentiviral vectors containing the variant did show significant phosphorylation of ERBB2 (Supplementary Figure 1) compared to WT (Figure 2A and B). The variant also exhibits an… (full text at CIViC) PMID 31046123 · Li et al., 2020 · Open in CIViC | civic |
| Nivolumab | Gastric Adenocarcinoma | Predictive | B | Does Not Support Resistance | 2 | accepted | EID13140In a retrospective cohort of gastric or gastroesophageal junction adenocarcinoma (n = 3116; ERBB2 R678Q n = 40), ERBB2 R678Q did not show a significant association with resistance to nivolumab-contain… (full text at CIViC) PMID 40699829 · Suzuki et al., 2025 · Open in CIViC | civic |
| Oxaliplatin | Gastric Adenocarcinoma | Predictive | B | Supports Resistance | 3 | |||
| ERBB2 R678Q + KRAS G12DERBB2KRAS1 | ||||||||
| (oncogenic) | Pancreatic Ductal Adenocarcinoma | Oncogenic | D | Supports Oncogenicity | 3 | submitted | EID11552KRAS G12D-transformed HPNE cells with lentiviral vectors containing the variant significantly increased colony formation in number and size in soft agar compared to infected HPNE cells with the varian… (full text at CIViC) PMID 31046123 · Li et al., 2020 · Open in CIViC | civic |
| ERBB2 S310F1 | ||||||||
| (oncogenic) | Pancreatic Ductal Adenocarcinoma | Oncogenic | D | Supports Oncogenicity | 3 | submitted | EID11547HPNE cells infected with lentiviral vectors containing the variant did show significant phosphorylation of ERBB2 (Supplementary Figure 1) compared to WT (Figure 2A and B). The variant also exhibits an… (full text at CIViC) PMID 31046123 · Li et al., 2020 · Open in CIViC | civic |
| ERBB2 S423R1 | ||||||||
| (oncogenic) | Pancreatic Ductal Adenocarcinoma | Oncogenic | D | Supports Oncogenicity | 3 | submitted | EID11549HPNE cells infected with lentiviral vectors containing the variant did show significant phosphorylation of ERBB2 (Supplementary Figure 1) compared to WT (Figure 2A and B). The variant also exhibits an… (full text at CIViC) PMID 31046123 · Li et al., 2020 · Open in CIViC | civic |
| ERBB2 V777L2 | ||||||||
| (oncogenic) | Pancreatic Ductal Adenocarcinoma | Oncogenic | D | Supports Oncogenicity | 3 | submitted | EID11559HPNE cells infected with lentiviral vectors containing the variant did show significant phosphorylation of ERBB2 (Supplementary Figure 1) compared to WT (Figure 2A and B). The variant also exhibits an… (full text at CIViC) PMID 31046123 · Li et al., 2020 · Open in CIViC | civic |
| Neratinib | Pancreatic Ductal Adenocarcinoma | Predictive | D | Supports Sensitivity Response | 3 | submitted | EID11569Neratinib suppresses anchorage-independent growth in transduced HPNE cells with the variant in a concentration-dependent manner (Figure 6B–C) with complete inhibition at a concentration of 0.5 µM (Fig… (full text at CIViC) PMID 31046123 · Li et al., 2020 · Open in CIViC | civic |
| ERBB2 V777L + KRAS G12CERBB2KRAS1 | ||||||||
| ARS-1620 + NeratinibCombination | Pancreatic Ductal Adenocarcinoma | Predictive | D | Supports Sensitivity Response | 3 | submitted | EID11572When tested in MIAPaCa2 (PDAC cell line and KRAS G12C) cells, Neratinib and ARS-1620 strongly inhibit AKT and MAPK phosphorylation (Figure 6F). Also, MIAPaCa2 cell line with the variant in exposure to… (full text at CIViC) PMID 31046123 · Li et al., 2020 · Open in CIViC | civic |
| ERBB2 V777L + KRAS G12DERBB2KRAS1 | ||||||||
| (oncogenic) | Pancreatic Ductal Adenocarcinoma | Oncogenic | D | Supports Oncogenicity | 3 | submitted | EID11560KRAS G12D-transformed HPNE cells with lentiviral vectors containing the variant significantly increased colony formation in number and size in soft agar compared to infected HPNE cells with the varian… (full text at CIViC) PMID 31046123 · Li et al., 2020 · Open in CIViC | civic |
| ERBB2 V842I1 | ||||||||
| (oncogenic) | Pancreatic Ductal Adenocarcinoma | Oncogenic | D | Supports Oncogenicity | 3 | submitted | EID11561HPNE cells infected with lentiviral vectors containing the variant did show significant phosphorylation of ERBB2 (Supplementary Figure 1) compared to WT (Figure 2A and B). The variant also exhibits an… (full text at CIViC) PMID 31046123 · Li et al., 2020 · Open in CIViC | civic |
| ERBB2 V842I1 | ||||||||
| Neratinib | Pancreatic Ductal Adenocarcinoma | Predictive | D | Supports Sensitivity Response | 3 | submitted | EID11570Neratinib suppresses anchorage-independent growth in transduced HPNE cells with the variant in a concentration-dependent manner (Figure 6B–C) with complete inhibition at a concentration of 0.5 µM (Fig… (full text at CIViC) PMID 31046123 · Li et al., 2020 · Open in CIViC | civic |
| ERBB2 V842I + KRAS G12DERBB2KRAS1 | ||||||||
| (oncogenic) | Pancreatic Ductal Adenocarcinoma | Oncogenic | D | Supports Oncogenicity | 3 | submitted | EID11562KRAS G12D-transformed HPNE cells with lentiviral vectors containing the variant significantly increased colony formation in number and size in soft agar compared to infected HPNE cells with the varian… (full text at CIViC) PMID 31046123 · Li et al., 2020 · Open in CIViC | civic |
| ERBB3 D297Y1 | ||||||||
| Afatinib + Cetuximab + ErlotinibSubstitutes | Esophageal Squamous Cell CarcinomaALIAS | Predictive | D | Does Not Support Sensitivity Response | 2 | submitted | EID9675In an in vitro study, an esophageal squamous cell carcinoma (ESCC) cell line KYSE150 expressing ERBB3 (HER3) D297Y mutation was associated with insensitivity to cetuximab, afatinib, and erlotinib trea… (full text at CIViC) PMID 27207775 · Nakamura et al., 2016 · Open in CIViC | civic |
| ERBB3 EXPRESSION1 | ||||||||
| 9F7-F11 + PertuzumabCombination | Pancreatic Ductal Adenocarcinoma | Predictive | D | Supports Sensitivity Response | 3 | accepted | EID865In mice xenografts expressing ERBB3 (HER3) the combination of ERBB2 (HER2) and ERBB3 inhibitors pertuzumab and 9F7-F11enhanced tumor inhibition and the median survival time. Sensitivity to single-agen… (full text at CIViC) PMID 25216528 · Thomas et al., 2014 · Open in CIViC | civic |
Data updated 12 hours agoSource updated unknownsource: civic (CC0)
Evidence levels, directions and ratings are those assigned by CIViC curators. "Submitted" items have not completed curation review. This is not treatment guidance.
| Prognostic |
| B |
| Supports Poor Outcome |
| 3 |
| rejected |
EID834Overexpression of EGFR in 55 samples of esophageal squamous cell carcinoma as assesesed by IHC, was related to poor OS and PFS (PFS: 5.8 ± 0.5 vs. 11.0 ± 2.8 months, P = 0.007; OS: 9.7 ± 0.5 vs. 21.5… (full text at CIViC) PMID 26459251 · Jia et al., 2016 · Open in CIViC |
| civic |
| Nimotuzumab | Esophageal Squamous Cell CarcinomaALIAS | Predictive | B | Does Not Support Sensitivity Response | 3 | accepted | EID78355 tumor samples were analyzed for EGFR expression using IHC. The objective response rate to anti-EGFR antibody nimotuzumab did not differ significantly between EGFR high- (18 pts) and EGFR low to mod… (full text at CIViC) PMID 26459251 · Jia et al., 2016 · Open in CIViC | civic |
| Predictive |
| B |
| Does Not Support Sensitivity Response |
| 3 |
| submitted |
EID11062The Medical Research Council (MRC) COIN trial consisted of patients with histologically confirmed adenocarcinoma of the colon or rectum, inoperable metastatic or locoregional measurable disease, and w… (full text at CIViC) PMID 21641636 · Maughan et al., 2011 · Open in CIViC |
| civic |
| 3 |
| accepted |
EID1023TyTAN, a Phase III study in Asian patients, looked at addition of tyrosine kinase inhibitor lapatinib to chemptherapy in advanced HER2 positive gastric cancer. Primary endpoint was Overall Survival (… (full text at CIViC) PMID 24868024 · Satoh et al., 2014 · Open in CIViC |
| civic |
| Chemotherapy + Pembrolizumab + TrastuzumabCombination | Gastroesophageal Junction Adenocarcinoma | Predictive | A | Supports Sensitivity Response | 4 | submitted | EID11252In this randomized, double-blind, placebo-controlled, Phase III trial, 264 patients were enrolled with histologically or cytologically confirmed diagnoses of previously untreated, locally advanced, un… (full text at CIViC) PMID 34912120 · Janjigian et al., 2021 · Open in CIViC | civic |
| Trastuzumab | Gastric Adenocarcinoma | Predictive | A | Supports Sensitivity Response | 4 | accepted | EID1499ToGA, a Phase III study (NCT01041404) addressed use of trastuzumab in HER2 positive (overexpression or amplification) advanced gastric cancer, where chemotherapy using fluoropyrimidine-based and plati… (full text at CIViC) PMID 20728210 · Bang et al., 2010 · Open in CIViC | civic |
| 〃 | Gastroesophageal Junction Adenocarcinoma | Predictive | A | Supports Sensitivity Response | 4 | submitted | EID11254In this open-label, randomized, phase II trial, 187 patients with HER2-positive gastric or gastroesophageal junction (GEJ) adenocarcinoma that had progressed while they were receiving at least two pre… (full text at CIViC) PMID 32469182 · Shitara et al., 2020 · Open in CIViC | civic |
| 〃 | Gastric Adenocarcinoma | Predictive | B | Supports Sensitivity Response | 4 | accepted | EID1022ToGA, a Phase III study (NCT01041404) addressed use of trastuzumab in HER2 positive advanced gastric cancer, where chemotherapy using fluoropyrimidine-based and platinum-based combinations had been co… (full text at CIViC) PMID 20728210 · Bang et al., 2010 · Open in CIViC | civic |
| Chemotherapy + TrastuzumabCombination | Gastroesophageal Junction Adenocarcinoma | Predictive | A | Supports Sensitivity Response | 5 | submitted | EID11256In this phase 3, open-label, randomized controlled trial, 594 patients (584 in the primary analysis) with HER2-positive amplification or overexpression gastric or gastroesophageal junction adenocarcin… (full text at CIViC) PMID 20728210 · Bang et al., 2010 · Open in CIViC | civic |
| Pertuzumab + TrastuzumabCombination | Cholangiocarcinoma | Predictive | C | Supports Sensitivity Response | 3 | accepted | EID7638A patient with cholangiocarcinoma harboring with ERBB2 amplification (3+) detected by circulating tumor DNA testing and confirmed by tissue-based testing was treated with trastuzumab and pertuzumab. T… (full text at CIViC) PMID 31453370 · Yarlagadda et al., 2019 · Open in CIViC | civic |
| accepted |
EID13138In a retrospective cohort of gastric or gastroesophageal junction adenocarcinoma (n = 3116; ERBB2 R678Q n = 40), ERBB2 R678Q was associated with reduced response to oxaliplatin-based regimens compared… (full text at CIViC) PMID 40699829 · Suzuki et al., 2025 · Open in CIViC |
| civic |
| Ramucirumab | Gastric Adenocarcinoma | Predictive | B | Does Not Support Resistance | 2 | accepted | EID13139In a retrospective cohort of gastric or gastroesophageal junction adenocarcinoma (n = 3116; ERBB2 R678Q n = 40), ERBB2 R678Q did not show a significant association with resistance to ramucirumab-conta… (full text at CIViC) PMID 40699829 · Suzuki et al., 2025 · Open in CIViC | civic |